VYNE Stock Analysis
VY
Uncovered
Vyne Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 12 full-time employees. The company went IPO on 2018-01-25. The firm is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. The firm's lead product candidate, FMX114, which is in Phase IIa, is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis (AD). The firm is also engaged in the pre-clinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Its initial BET inhibitor candidate in development is VYN201, a locally administered pan-BET inhibitor, which the Company is exploring in various immuno-inflammatory diseases, including skin diseases. Its VYN202 is a pan-BD BET inhibitor that is being developed to address diseases involving multiple, diverse inflammation. In addition, the Company continues to explore opportunistic transactions that enhance its pipeline portfolio, as well as support its operations and fund its future growth.